Sequent Scientific Share Price Today | Stock Price & Sequent Scientific Share Screener
As of January 21, 2026, the live Sequent Scientific share price (NSE: SEQUENT) is ₹193.98 on NSE and ₹194.10 on BSE, down 2.73% from the previous close, with shares trading between ₹192.62 and ₹199.89 in today's trading session, and a 52-week range of ₹190.05–₹252.00. Check SEQUENT price range for the annual price range and momentum. Use the Sequent Scientific stock screener below to analyse P/E ratio, market cap, quarterly results, and more. See at what price today Sequent Scientific opened, then compare its market price and price volume with top gainers and top losers on the exchange. Record your trades in TickJournal's free trading journal and track your portfolio performance.
Key Statistics and Valuation Ratios
Over the trailing twelve months the company reported revenue of ₹403 and net income of ₹10, with EBITDA of ₹48, an operating margin of 11.0% and a profit margin of 2.5%.
Sequent Scientific Share Price Chart
Track the current stock price of Sequent Scientific with an interactive chart. Analyse SEQUENT share price trends, closing price, trading volume, historical performance, and volatility using live market data across different timeframes, from the last 30 days to the full record — the complete Sequent Scientific stock quote in one place.
The quote of ₹193.98 sits between the 52-week low of ₹190.05 and the 52-week high of ₹252.00, and the latest session moved -2.73% from the previous close.
Sequent Scientific Company Profile - Fundamental Screener
Screen Sequent Scientific company fundamentals and business profile. Use our stock screener to analyze sector, industry, and key company metrics for SEQUENT shares across the equity market and its stock price history, plus the wider market trend.
The company is classified under the Healthcare sector and the Pharmaceuticals industry, and it trades under ISIN INE807F01027.
Company Details
Classification
Identifiers and Leadership
Sequent Scientific Balance Sheet Screener
Screen SEQUENT balance sheet fundamentals including assets, liabilities, and equity. Use our screener tool to analyze financial health and share price valuation metrics, then compare equity shares and the debt-to-equity rate against peers in the stock market.
For 2025, total assets were ₹1,602 against total liabilities of ₹1,602, up from ₹1,540 in 2024.
Latest statistics put total assets at ₹1,602 and shareholder funds at ₹770, with a leverage ratio of 0.71.
| Item | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
Assets |
||||||||||
| Total Assets | 1,602 | 1,540 | 1,529 | 1,451 | 1,393 | 1,463 | 1,388 | 1,343 | 1,905 | 1,528 |
| Current Assets | 873 | 811 | 780 | 783 | 714 | 704 | 600 | 538 | 728 | 491 |
| Fixed Assets | 586 | 592 | 605 | 564 | 536 | 577 | 498 | 476 | 684 | 587 |
Liabilities |
||||||||||
| Total Liabilities | 1,602 | 1,540 | 1,529 | 1,451 | 1,393 | 1,463 | 1,388 | 1,343 | 1,905 | 1,528 |
| Current Liabilities | 327 | 200 | 221 | 199 | 156 | 236 | 207 | 227 | 247 | 290 |
| Non-Current Liabilities | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
Shareholders' Equity |
||||||||||
| Total Equity | 770 | 713 | 749 | 740 | 776 | 732 | 747 | 685 | 994 | 948 |
| Share Capital | 50 | 50 | 50 | 50 | 50 | 50 | 49 | 49 | 49 | 48 |
| Reserves & Surplus | 654 | 607 | 649 | 633 | 678 | 637 | 657 | 599 | 928 | 885 |
Sequent Scientific Income Statement Screener - Profit & Revenue Analysis
Screen Sequent Scientific income statement and profit fundamentals. Analyze SEQUENT quarterly results. Sequent Scientific reports revenue growth, EBITDA, net profit margins, and EPS, and TickJournal's fundamental screener helps with stock evaluation and equity returns.
For 2025-Mar, revenue was ₹403 and net profit was ₹10, equal to earnings per unit of ₹0.37, at an operating margin of 11%.
In that period expenses were ₹356, interest cost ₹15 and tax ₹6. The next period listed, 2025-Jun, shows revenue of ₹445 and net profit of ₹18.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec | 2023-Mar | 2023-Jun | 2023-Sept | 2023-Dec | 2022-Mar | 2022-Jun | 2022-Sept | 2022-Dec |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
Revenue and Expenses | |||||||||||||||
| Revenue | 403 | 445 | 426 | 365 | 393 | 373 | 397 | 368 | 334 | 356 | 337 | 388 | 342 | 339 | 378 |
| Expenses | 356 | 391 | 370 | 334 | 348 | 334 | 357 | 432 | 365 | 331 | 307 | 350 | 342 | 335 | 365 |
Operating Costs and Margins | |||||||||||||||
| EBITDA | 48 | 55 | 56 | 32 | 45 | 39 | 40 | -63 | -31 | 25 | 30 | 37 | 0 | 4 | 13 |
| Operating Profit % | 11.00% | 12.00% | 13.00% | 8.00% | 11.00% | 9.00% | 9.00% | -18.00% | -10.00% | 4.00% | 7.00% | 9.00% | 0.00% | 1.00% | 3.00% |
| Depreciation | 16 | 15 | 16 | 17 | 16 | 17 | 17 | 15 | 14 | 15 | 16 | 13 | 14 | 13 | 14 |
| Interest | 15 | 14 | 14 | 12 | 16 | 14 | 15 | 11 | 11 | 13 | 13 | 6 | 7 | 8 | 10 |
Profit and Earnings | |||||||||||||||
| Profit Before Tax | 16 | 26 | 27 | 3 | 12 | 8 | 8 | -89 | -56 | -3 | 2 | 18 | -21 | -18 | -10 |
| Tax | 6 | 8 | 8 | 1 | 3 | 2 | 2 | 4 | -21 | 4 | -9 | 8 | -6 | -13 | 0 |
| Net Profit | 10 | 18 | 20 | 1 | 9 | 6 | 7 | -92 | -35 | -7 | 11 | 10 | -15 | -4 | -10 |
| EPS | 0.37 | 0.57 | 0.59 | -0.04 | 0.26 | 0.11 | 0.14 | -3.77 | -1.40 | -0.34 | 0.33 | 0.36 | -0.60 | -0.15 | -0.36 |
Sequent Scientific Cash Flow Screener - Liquidity Fundamentals
Screen SEQUENT cash flow statements and liquidity fundamentals. Analyze operating, investing, and financing activities using our stock screener for share price strength and price trend assessment against the wider stock market and other stocks.
In 2025-March, operating activities generated ₹83, and net cash flow was an outflow of ₹2.
Over the same period, investing activities used ₹25 and financing activities used ₹61.
| Item | 2025-March | 2024-March | 2023-March | 2022-March | 2021-March | 2020-March | 2019-March | 2018-March | 2017-March | 2016-March |
|---|---|---|---|---|---|---|---|---|---|---|
Cash from Operations and Investing | ||||||||||
| Operating Activities | 83 | 31 | 17 | 31 | 115 | 115 | 116 | 45 | -7 | 0 |
| Investing Activities | -25 | -6 | -65 | -94 | 10 | -72 | -68 | 7 | -116 | -311 |
Financing and Net Cash | ||||||||||
| Financing Activities | -61 | -1 | 32 | 67 | -139 | -43 | -20 | -57 | 147 | 309 |
| Net Cash Flow | -2 | 23 | -16 | 4 | -14 | 0 | 28 | -5 | 24 | -2 |
Sequent Scientific Shareholding Pattern Screener
See Sequent Scientific shareholding pattern with promoter, FII, and DII holdings. Check Sequent Scientific promoter holding and ownership changes for SEQUENT on TickJournal, and see how institutional stock price moves affect the market.
In 2025-Mar, promoters held 52.61%, foreign institutions 6.05%, domestic institutions 12.82% and the public 23.43%, spread across 158,152 shareholders.
The shareholder count was 158,152 in 2025-Mar, compared with 147,320 in 2025-Jun.
| Item | 2025-Mar | 2025-Jun | 2025-Sept | 2025-Dec | 2024-Mar | 2024-Jun | 2024-Sept | 2024-Dec |
|---|---|---|---|---|---|---|---|---|
Promoter Holding | ||||||||
| Promoter Holding | 52.61% | 52.61% | 52.33% | 61.43% | 52.79% | 52.78% | 52.76% | 52.61% |
Institutional Investors | ||||||||
| FII Holding | 6.05% | 6.15% | 5.91% | 3.16% | 6.16% | 5.70% | 6.45% | 6.10% |
| DII Holding | 12.82% | 12.98% | 12.91% | 7.35% | 7.59% | 8.06% | 9.99% | 12.02% |
Government, Public and Others | ||||||||
| Govt Holding | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% | 0.00% |
| Public Holding | 23.43% | 22.37% | 22.72% | 19.24% | 24.43% | 25.01% | 24.00% | 23.82% |
| Other Holding | 5.09% | 5.89% | 6.13% | 8.83% | 9.02% | 8.45% | 6.80% | 5.46% |
| Shareholder Count | 158,152 | 147,320 | 144,085 | 135,389 | 166,593 | 163,693 | 154,603 | 162,574 |
Dividend Yield Screener - Share Price & Share Analysis
Check the dividend history with payout and yield data. View dividend details including ex-dates, the dividend rate, and amounts paid by Sequent Scientific. Sequent Scientific dividend yield can be compared with peers and other stocks in the market.
The latest dividend recorded was ₹0.00 per unit for 2026-March, a yield of 0.00%, compared with ₹0.00 for 2025-March.
Dividends are listed for 10 periods, with the three most recent payouts at ₹0.00, ₹0.00 and ₹0.00 per unit.
| Period | Dividend Per Share | Dividend Yield |
|---|---|---|
| 2026-March | ₹0.00 | 0.00% |
| 2025-March | ₹0.00 | 0.00% |
| 2024-March | ₹0.00 | 0.00% |
| 2023-March | ₹0.00 | 0.00% |
| 2022-March | ₹0.00 | 0.00% |
| 2021-March | ₹0.50 | 0.37% |
| 2020-March | ₹0.00 | 0.00% |
| 2019-March | ₹0.20 | 0.26% |
| 2018-March | ₹0.20 | 0.28% |
| 2017-March | ₹0.00 | 0.00% |
Sequent Scientific Stock Index Membership - Nifty & Sensex
See which indices include Sequent Scientific stock. Check SEQUENT index membership in NIFTY 50, SENSEX, and other indices on TickJournal, and compare the Nifty trend with the broader market trend.
The company is listed in 5 indices, including BSE 1000.
Among the benchmarks tracked are BSE 1000, BSE INDEX BSE HC, BSE INDEX SMLCAP, NIFTY MICROCAP250.
Complete Index List
Sequent Scientific Market Events Screener - Corporate Actions
Get Sequent Scientific corporate actions including splits, bonuses, and buybacks disclosed to the exchange. Check Sequent Scientific stock events that may affect SEQUENT share price, along with derivatives, futures and options activity and sector gainers.
11 corporate actions are listed, the most recent entry being Dividend dated .
It is followed by Annual General Meeting dated and Merger - Demerger dated December 8, 2025.
| Announcement Date | Record Date | Event Type | Information | Price Impact |
|---|---|---|---|---|
| Dividend | ₹ 0.50 /share | -26.73% | ||
| Annual General Meeting | NA | 7.61% | ||
| 2025-12-08 | 2025-12-08 | Merger - Demerger | 100:56 | 0.00% |
| 2025-11-14 | 2025-11-14 | Quarterly Result Announcement | NA | 6.35% |
| 2025-08-30 | 2025-08-30 | Extraordinary General Meeting | NA | -2.53% |
| 2025-08-26 | 2025-08-26 | Extraordinary General Meeting | NA | -0.29% |
| 2025-08-08 | 2025-08-08 | Quarterly Result Announcement | NA | -0.48% |
| 2025-08-08 | 2025-08-08 | Annual General Meeting | NA | -3.66% |
| 2025-05-20 | 2025-05-20 | Quarterly Result Announcement | NA | 15.69% |
| 2025-02-11 | 2025-02-11 | Quarterly Result Announcement | NA | -2.09% |
| 2024-11-13 | 2024-11-13 | Quarterly Result Announcement | NA | -3.87% |
Sequent Scientific Competitors Screener - Peer Stocks Comparison
Screen SEQUENT competitors and compare share prices across peer stocks. Use our screener to analyze sector peers, fundamentals, and relative performance, from valuation and price target to the future price outlook, for better stock selection in a changing stock market.
The comparison table covers 10 companies in the Healthcare sector, shown with market capitalisation, P/E ratio, revenue, growth, net profit and RSI.
| Company | Market Cap | P/E Ratio | Revenue | YoY Growth | Net Profit | RSI |
|---|---|---|---|---|---|---|
| Sun Pharmaceutical | 387,205 | 38.30 | 54,729 | 9.71% | 10,980 | 26.52 |
| Divis Laboratories | 159,626 | 65.60 | 9,712 | 18.67% | 2,191 | 29.62 |
| Torrent Pharmaceuticals | 134,593 | 64.70 | 11,539 | 6.99% | 1,911 | 56.71 |
| Cipla | 111,343 | 20.68 | 28,410 | 7.12% | 5,291 | 23.28 |
| Lupin | 99,048 | 22.89 | 22,910 | 13.74% | 3,306 | 57.69 |
| Dr Reddys Laboratories | 97,376 | 16.97 | 33,741 | 16.73% | 5,725 | 23.20 |
| Zydus Life Science | 87,884 | 17.63 | 23,511 | 18.55% | 4,615 | 34.17 |
| Mankind Pharma | 87,692 | 49.29 | 12,744 | 20.90% | 2,007 | 40.97 |
| Alkem Laboratories | 68,397 | 28.48 | 13,458 | 3.70% | 2,216 | 52.47 |
| Aurobindo Pharma | 66,310 | 19.82 | 32,346 | 9.43% | 3,484 | 35.55 |
Sequent Scientific Company Announcements - News & Reports Screener
Screen SEQUENT latest company announcements and news updates. Filter stock news, results, and material events using our screener for share price impact analysis, and review the option chain for related stocks. Compare other stocks in the same sector.
20 recent announcements are listed, the latest dated January 21, 2026.
The next most recent announcements are dated January 9, 2026 and January 9, 2026.
| Date | Update | Actions |
|---|---|---|
| 2026-01-21 | Announcement under Regulation 30 (LODR)-Credit Rating | - |
| 2026-01-09 | Intimation Of Change Of Name Of The Company. | - |
| 2026-01-09 | Compliances-Certificate under Reg. 74 (5) of SEBI (DP) Regulations 2018 | - |
| 2025-12-30 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2025-12-29 | Shareholder Meeting / Postal Ballot-Scrutinizer"s Report | - |
| 2025-12-23 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2025-12-19 | Closure of Trading Window | - |
| 2025-12-17 | Disclosures under Reg. 10(6) of SEBI (SAST) Regulations 2011 | - |
| 2025-12-17 | Disclosures under Reg. 29(2) of SEBI (SAST) Regulations 2011 | - |
| 2025-12-17 | Disclosures under Reg. 29(1) of SEBI (SAST) Regulations 2011 | - |
| 2025-12-16 | Announcement under Regulation 30 (LODR)-Scheme of Arrangement | - |
| 2025-12-16 | Announcement under Regulation 30 (LODR)-Change in Management | - |
| 2025-12-16 | Board Meeting Outcome for Intimation Under Regulation 30 Of SEBI (Listing Obligations And Disclosure Requirements) Regulations 2025 (SEBI Listing Regulations) And Outcome Of Board Meeting Of The Company | - |
| 2025-12-11 | Announcement under Regulation 30 (LODR)-Allotment of ESOP / ESPS | - |
| 2025-11-29 | Announcement under Regulation 30 (LODR)-Newspaper Publication | - |
| 2025-11-28 | Shareholder Meeting / Postal Ballot-Notice of Postal Ballot | - |
| 2025-11-28 | Announcement under Regulation 30 (LODR)-Scheme of Arrangement | - |
| 2025-11-27 | Announcement under Regulation 30 (LODR)-Amendments to Memorandum & Articles of Association | - |
| 2025-11-26 | Intimation Of Record Date Under Regulation 42 Of SEBI | - |
| 2025-11-22 | Announcement under Regulation 30 (LODR)-Scheme of Arrangement | - |
Frequently Asked Questions
How is the company valued right now?
The current quote is ₹193.98, within a 52-week range of ₹190.05 to ₹252.00. The P/E ratio is 165.81 and the P/B ratio is 10.60, with earnings per unit of ₹0.88. Market capitalisation stands at ₹5,067.77 Cr. The company operates in the Healthcare sector, in the Pharmaceuticals industry, so compare these ratios with its sector peers in the table above.
About This Data
Quotes are sourced from the NSE and the BSE. Key statistics were last updated on January 23, 2026. This page covers 10 balance sheet periods, 15 income statement periods, 10 cash flow years and 8 shareholding periods. Information is provided for research and is not investment advice.